Corynebacterium aurimucosum

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Corynebacterium aurimucosum is a Gram-positive, non-spore-forming, facultatively anaerobic, non-motile, coryneform bacterium. It has been detected in at least 3 gut microbiome compilation studies or metastudies. The DNA G+C content is 63.7%. Corynebacterium aurimucosum is probably a rare gut coloniser. (Daneshvar2004; Yassin2002; Bernard2012Bergey)



  • This organism has been recovered from human faeces and various clinical specimens. The risk classification (www.baua.de) for this organism is 1, i.e., low risk of infection and spread (notes: opportunistic in immunocompromised patients). It is an opportunistic pathogen. Is a known gut commensal.
    • GENERAL CHARACTERISTICS (Daneshvar2004); (Yassin2002); (Bernard2012Bergey);
    Character Response
  • Substrates hydrolysed or digested:
  • hippurate;
  • ±
  • Strain-dependent hydrolysis or digestion:
  • aesculin; gelatin; urea;
  • H+
  • Acid from carbohydrates usually produced:
  • fructose; glucose; maltose; sucrose;
  • ±
  • Strain-dependent acid from carbs:
  • mannitol;
  • Active enzymes:
  • Ala-Phe-Pro arylamidase; catalase;
  • ±
  • Strain-dependent active enzymes:
  • oxidase;
    • SPECIAL FEATURES (Daneshvar2004); (Yassin2002);
    Character Response
  • ✓
  • Metabolites produced:
  • lactate (major);
  • ✗
  • Metabolites not produced:
  • propionate; indole;
  • ✓
  • VP test:
  • active
  • ✗
  • Nitrate:
  • not reduced
    • RESPONSE TO ANTIBIOTICS (Tyrrell2012); (Goldstein2008); (Goldstein2006a);
    Class Active Resistant
  • Penicillins:
  • ampicillin;
  • ampicillin-sulbactam; piperacillin-tazobactam;
  • Cephalosporins:
  • ceftazidime;
  • Vancomycins:
  • vancomycin;
  • Miscellaneous antibiotics:
  • daptomycin; linezolid;
  • clindamycin;

  • Lagier, J.-C., Armougom, F., Million, M., Hugon, P., Pagnier, I., Robert, C., Bittar, F., Fournous, G., Gimenez, G., Maraninchi, M., Trape, J.-F., Koonin, E. V., La Scola, B., & Raoult, D. (2012). Microbial culturomics: paradigm shift in the human gut microbiome study. Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 18(12), 1185–1193.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Actinobacteria Class:  Actinomycetia Order:  Corynebacteriales Family:  Corynebacteriaceae Genus:  Corynebacterium Gram stain:  + O2 Relation.:  facultatively anaerobic Spore:  No spore Motility:  Sessile Morphology:  Coryneform
    Health:  Unknown
    Source:  human faeces and various clinical specimens
    DNA G+C(%):  63.7
    		Aesculin:  d Urea:  d(neg) Gelatin:  d(neg) Starch:  neg Hippurate:  +
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  neg L-Arabinose:  neg Fructose:  + Glucose:  + Mannose:  neg Rhamnose:  neg Ribose:  neg D-Tagatose:  neg Xylose:  neg Cellubiose:  neg Lactose:  neg Maltose:  + Melezitose:  neg Sucrose:  + Trehalose:  neg Amygdalin:  neg Dextrin:  neg Glycogen:  neg Inulin:  neg Adonitol:  neg D-Arabitol:  neg Glycerol:  neg Mannitol:  d(neg) Sorbitol:  neg Salicin:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Oxidase:  d(neg) Catalase:  + Urease:  neg Ac-β-glcamnd:  neg α-Fucosidase:  neg α-Galactosidase:  neg β-Galactosidase:  neg α-Glucosidase:  neg β-Glucosidase:  neg β-Glucuronidase:  neg α-Mannosidase:  neg β-Mannosidase:  neg ArgDH:  neg Chymotrypsin:  neg Trypsin:  neg AlaPheProAA:  + CystineAA:  neg LeuAA:  vr PyrrolidAA:  neg ValAA:  neg AlkalineP:  vr AcidP:  neg Esterase(C4):  neg EstLip(C8):  neg Lipase(C14):  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Propionate:  neg Lactate:  Major(+) Indole:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    ampicillin:  S(MIC50): 1, MIC90: >32, RNG: (0.03–32)
    amp-sulb:  R(MIC50): >64, MIC90: >64, RNG: (1–>64)
    piper-taz:  R(MIC50): >128, MIC90: >128, RNG: (8–>128)
    doripenem:  Var(MIC50): 1, MIC90: 8, RNG: (0.25–>32)
    ertapenem:  Var(MIC50): 1, MIC90: 32, RNG: (0.5–>32)
    imipenem:  Var(MIC50): 0.25, MIC90: 32, RNG: (0.06–>32)
    meropenem:  Var(MIC50): 1, MIC90: 16, RNG: (0.125–>32)
    cefepime:  Var(MIC50): 1, MIC90: >32, RNG: (0.06–>32)
    cefotaxime:  Var(MIC50): 1, MIC90: >32, RNG: (0.03->32)
    cefoxitin:  Var(MIC50): 8, MIC90: 64, RNG: (0.125–>128)
    ceftazidime:  R(MIC50): 32, MIC90: >64, RNG: (0.5–>64)
    linezolid:  S(MIC50): 0.5, MIC90: 1, RNG: (0.25–2)
    levofloxacin:  Var(MIC50): 0.25, MIC90: >16, RNG: (0.125–>16)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    vancomycin:  S(MIC50): 0.5, MIC90: 0.5, RNG: (0.125–1)
    clindamycin:  R(MIC50): >64, MIC90: >64, RNG: (>64–>64)
    daptomycin:  S(MIC50): 0.5, MIC90: 2, RNG: (0.06–2)

    References

    SPECIFIC REFERENCES FOR CORYNEBACTERIUM AURIMUCOSUM
  • Daneshvar2004 - Identification of Some Charcoal-Black-Pigmented CDC Fermentative Coryneform Group 4 Isolates as Rothia dentocariosa and Some as Corynebacterium aurimucosum : Proposal of Rothia dentocariosa emend. Georg and Brown 1967, Corynebacterium aurimucosum emend. Yassin et al. 2002, and Corynebacterium nigricans Shukla et al. 2003 pro synon. Corynebacterium aurimucosum.
  • Yassin2002 - Corynebacterium aurimucosum sp. nov. and emended description of Corynebacterium minutissimum Collins and Jones (1983).
  • Bernard2012Bergey - Bergey's manual of systematic bacteriology. Vol. 5, The Actinobacteria. Part A & B. Corynebacteriaceae, Genus I. Corynebacterium
  • Tyrrell2012 - In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species.
  • Goldstein2008 - In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
  • Goldstein2006a - In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR CORYNEBACTERIUM AURIMUCOSUM
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • ...............................
    • Added: April 08, 2021